Cargos activos de Ruben J. Boado
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Director Técnico/Científico/I+D | 01/01/2004 | - |
| Fundador | 01/01/2004 | - |
Historial de carrera de Ruben J. Boado
Antiguos cargos conocidos de Ruben J. Boado.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| University of California, Los Angeles | Corporate Officer/Principal | - | - |
Formación de Ruben J. Boado.
| Universidad de Buenos Aires | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Argentina | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Doctorate Degree | 1 |
Sectorial
| Consumer Services | 3 |
| Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
- Bolsa de valores
- Insiders
- Ruben J. Boado
- Experiencia
